Literature DB >> 1513680

Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?

D S Burke1.   

Abstract

Antibody-dependent enhancement is a general in vitro property of enveloped viruses. In certain circumstances, antibody-dependent enhancement is a bona fide pathophysiologic mechanism in vivo. There are several examples of virus disease of humans and animals in which incomplete or partial immunity can lead to enhanced infection and/or disease. In some cases, this appears to be attributable to antibody-dependent enhancement. Conversely, there are several examples of viruses for which in vitro antibody-dependent enhancement has been demonstrated, but for which vaccines have been used safely in millions of persons for decades. Finally, antibody-dependent enhancement of HIV is a genuine concern. However, to date there is no direct clinical, experimental, or epidemiological evidence that HIV enhancement can be operative in vivo. Such evidence should be actively sought.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1513680     DOI: 10.1353/pbm.1992.0048

Source DB:  PubMed          Journal:  Perspect Biol Med        ISSN: 0031-5982            Impact factor:   1.416


  12 in total

1.  Dynamic effects of antibody-dependent enhancement on the fitness of viruses.

Authors:  Derek A T Cummings; Ira B Schwartz; Lora Billings; Leah B Shaw; Donald S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

2.  Causal Vaccine Effects on Binary Postinfection Outcomes.

Authors:  Michael G Hudgens; M Elizabeth Halloran
Journal:  J Am Stat Assoc       Date:  2006-03       Impact factor: 5.033

Review 3.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.

Authors:  J Townsley-Fuchs; L Kam; R Fairhurst; S J Gange; L Goodglick; J V Giorgi; N Sidell; R Detels; J Braun
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Evaluating the efficacy of a malaria vaccine.

Authors:  Dylan S Small; Jing Cheng; Thomas R Ten Have
Journal:  Int J Biostat       Date:  2010-02-22       Impact factor: 0.968

Review 6.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

Review 7.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

Review 8.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

Review 9.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

10.  Perspective: The promises of a holistic view of proteins-impact on antibody engineering and drug discovery.

Authors:  Ser-Xian Phua; Kwok-Fong Chan; Chinh Tran-To Su; Jun-Jie Poh; Samuel Ken-En Gan
Journal:  Biosci Rep       Date:  2019-01-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.